Virbagen Omega 10 MU Lyophilisate and Solvent for Suspension for Injection for Dogs and Cats

No information on the induction of long-term adverse reactions is available in dog and cat,
especially for autoimmune disorders. Such adverse effects have been described after
multiple and long-term administration of type I interferon in man. The possibility of
occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and
has to be balanced with the risk associated with FeLV/FIV infections.
Efficacy of the veterinary medicinal product on cats with a tumorous form of the infection
by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.
In the case of intravenous administration in cats, increased adverse reactions may be
seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.

Special precautions for safe use in the target species:
Dogs and cats: it was shown that strict compliance with the recommended posology is
compulsory to achieve clinical benefit.
Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac
and renal failure, the corresponding disease has to be monitored prior to administration of
this veterinary medicinal product.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.